JP2022551228A5 - - Google Patents

Info

Publication number
JP2022551228A5
JP2022551228A5 JP2022516163A JP2022516163A JP2022551228A5 JP 2022551228 A5 JP2022551228 A5 JP 2022551228A5 JP 2022516163 A JP2022516163 A JP 2022516163A JP 2022516163 A JP2022516163 A JP 2022516163A JP 2022551228 A5 JP2022551228 A5 JP 2022551228A5
Authority
JP
Japan
Prior art keywords
antibiotic
rifabutin
item
formulation
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551228A (ja
JP7804570B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000645 external-priority patent/WO2021048610A1/en
Publication of JP2022551228A publication Critical patent/JP2022551228A/ja
Publication of JP2022551228A5 publication Critical patent/JP2022551228A5/ja
Priority to JP2025145104A priority Critical patent/JP2025176113A/ja
Application granted granted Critical
Publication of JP7804570B2 publication Critical patent/JP7804570B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516163A 2019-09-12 2020-08-03 抗生物質併用療法 Active JP7804570B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025145104A JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025145104A Division JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法

Publications (3)

Publication Number Publication Date
JP2022551228A JP2022551228A (ja) 2022-12-08
JP2022551228A5 true JP2022551228A5 (cg-RX-API-DMAC7.html) 2023-08-14
JP7804570B2 JP7804570B2 (ja) 2026-01-22

Family

ID=72432957

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022516163A Active JP7804570B2 (ja) 2019-09-12 2020-08-03 抗生物質併用療法
JP2022516161A Active JP7769605B2 (ja) 2019-09-12 2020-08-03 リファブチン処置法、使用および組成物
JP2025145104A Pending JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法
JP2025184422A Pending JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022516161A Active JP7769605B2 (ja) 2019-09-12 2020-08-03 リファブチン処置法、使用および組成物
JP2025145104A Pending JP2025176113A (ja) 2019-09-12 2025-09-02 抗生物質併用療法
JP2025184422A Pending JP2026016690A (ja) 2019-09-12 2025-10-31 リファブチン処置法、使用および組成物

Country Status (17)

Country Link
US (6) US11351158B2 (cg-RX-API-DMAC7.html)
EP (3) EP4028001B1 (cg-RX-API-DMAC7.html)
JP (4) JP7804570B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991225B1 (cg-RX-API-DMAC7.html)
CN (3) CN115052597B (cg-RX-API-DMAC7.html)
AU (2) AU2020347536B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004645A2 (cg-RX-API-DMAC7.html)
CA (2) CA3154317A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982067T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240818T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066936T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022003077A (cg-RX-API-DMAC7.html)
PH (1) PH12022550610A1 (cg-RX-API-DMAC7.html)
PL (1) PL4028001T3 (cg-RX-API-DMAC7.html)
RS (1) RS65681B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400250T1 (cg-RX-API-DMAC7.html)
WO (2) WO2021048610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012106364A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
EP3189154B1 (en) * 2014-09-04 2023-03-22 Labrador Diagnostics LLC Pathogen and antimicrobial resistance testing
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Similar Documents

Publication Publication Date Title
Matovu et al. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle
Xun et al. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells
JP2020023528A5 (cg-RX-API-DMAC7.html)
WO2021147235A1 (zh) 法匹拉韦在治疗冠状病毒感染方面的应用
Sri et al. Antiviral treatment of COVID-19: a clinical pharmacology narrative review
JP2024515829A5 (cg-RX-API-DMAC7.html)
JP2022523726A5 (cg-RX-API-DMAC7.html)
JP2022537047A5 (cg-RX-API-DMAC7.html)
JP2022514759A5 (cg-RX-API-DMAC7.html)
JP2013503880A5 (cg-RX-API-DMAC7.html)
PH12022552516A1 (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease
Qu et al. COVID-19: the epidemiology and treatment
Ferreira et al. COVID-19: small-molecule clinical trials landscape
Rodríguez et al. Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection
JP2022519007A5 (cg-RX-API-DMAC7.html)
JP2025176113A5 (cg-RX-API-DMAC7.html)
CN104039955A (zh) 新噬菌体
JPWO2023210732A5 (cg-RX-API-DMAC7.html)
Irie et al. Treatment of coronavirus disease 2019 with saikatsugekito: a case series
Dang et al. Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events
MX2025012741A (es) Composiciones farmaceuticas orales
Ranjan et al. Preclinical development of inhalable D-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis
Wang et al. Genomic comparison between attenuated Chinese equine infectious anemia virus vaccine strains and their parental virulent strains
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
JP2022526643A5 (cg-RX-API-DMAC7.html)